title: Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model.
abstract: OBJECTIVE
  To reduce adverse effects and improve efficacy of intravesical BCG for bladder cancer, alternative treatment options were investigated in an orthotopic rat tumor model.
  
  
  METHODS
  Superficial bladder cancer was established in syngeneic female rat bladders by instillation of AY-27 cells. Animals were randomly assigned to treatment groups including dose escalation of intravesical BCG with or without interferon-α (IFN-α) or interleukin-2 (IL-2); or graded doses of gemcitabine alone; or BCG plus gemcitabine. Treatments were given twice weekly for 3 weeks. Rats in control groups received saline instillations. Treatment response was monitored by animals' well-being, survival days, tumor growth inhibition, and histological examination at necropsy.
  
  
  RESULTS
  Rats receiving monotherapy with intravesical BCG, gemcitabine, or IFN-α, attained significantly better survival and tumor reduction compared with control (P = 0.002; 0.001; 0.002, respectively, Log-rank Test). A dose-dependent treatment response was observed in animals with established bladder tumor receiving escalated BCG instillations. Only high-dose BCG significantly improved animal survival. Although high-dose BCG plus gemcitabine or IFN-α did not increase benefit over monotherapies, low-dose BCG plus IL-2 did show improved efficacy (P = 0.01).
  
  
  CONCLUSIONS
  Intravesical monotherapies with gemcitabine and IFN-α were as effective as BCG for treatment of early non-muscle-invasive urothelial bladder cancer in this immune competent rat model. Combining these agents with high-dose BCG did not further increase efficacy. However, combining low-dose BCG with IL-2 enhanced BCG effectiveness.
authors.affiliation: Departments of Surgery and Oncology, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Zhengwen
authors.initials: Z
authors.lastname: Xiao
authors.forename: Erich
authors.initials: E
authors.lastname: Hanel
authors.forename: Allan
authors.initials: A
authors.lastname: Mak
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Moore
references.citation: Int Urol Nephrol. 2000;32(1):53-8
references.pmid: 11057773
references.citation: J Urol. 1985 Jul;134(1):40-7
references.pmid: 3892050
references.citation: Int J Cancer. 2003 Nov 10;107(3):434-40
references.pmid: 14506744
references.citation: Urol Clin North Am. 1992 Aug;19(3):565-72
references.pmid: 1636240
references.citation: J Urol. 2003 Feb;169(2):718-20
references.pmid: 12544350
references.citation: J Urol. 2004 Nov;172(5 Pt 1):2018-22
references.pmid: 15540781
references.citation: BJU Int. 2008 Apr;101(7):889-93
references.pmid: 18201266
references.citation: Rev Urol. 2008 Fall;10(4):281-9
references.pmid: 19145271
references.citation: Br J Cancer. 1999 Oct;81(4):638-46
references.pmid: 10574249
references.citation: Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78
references.pmid: 11514784
references.citation: J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5
references.pmid: 11547062
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3193-8
references.pmid: 12149290
references.citation: Cancer Res. 2004 May 15;64(10):3386-90
references.pmid: 15150089
references.citation: J Urol. 2002 Apr;167(4):1573-83
references.pmid: 11912367
references.citation: Clin Cancer Res. 1999 Sep;5(9):2629-37
references.pmid: 10499642
references.citation: J Clin Oncol. 2003 Feb 15;21(4):697-703
references.pmid: 12586808
references.citation: Immunol Res. 2007;39(1-3):79-93
references.pmid: 17917057
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2729-34
references.pmid: 16782913
references.citation: J Urol. 2006 Feb;175(2):432-8
references.pmid: 16406966
references.citation: J Urol. 1992 Apr;147(4):1020-3
references.pmid: 1552578
references.citation: Eur J Cancer. 1999 Jul;35(7):1123-9
references.pmid: 10533458
references.citation: Semin Urol. 1992 Feb;10(1):39-44
references.pmid: 1565903
references.citation: Int J Oncol. 2011 Jul;39(1):61-71
references.pmid: 21537842
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Urol. 2003 Jan;169(1):352-6
references.pmid: 12478188
references.citation: J Urol. 2008 Jan;179(1):53-6
references.pmid: 17997439
references.citation: Br J Cancer. 2009 Aug 18;101(4):628-36
references.pmid: 19672265
references.citation: Cancer Immunol Immunother. 2003 Aug;52(8):481-6
references.pmid: 12707736
references.citation: Gene Ther. 2000 May;7(10):844-51
references.pmid: 10845722
references.citation: Int J Cancer. 2001 Jun 1;92(5):697-702
references.pmid: 11340575
references.citation: J Urol. 2004 Sep;172(3):888-93
references.pmid: 15310991